Tirzepatide vs Dulaglutide

Tirzepatide vs Dulaglutide: Overview

Tirzepatide and dulaglutide are both manufactured by the same pharmaceutical company and target incretin receptor pathways, yet they represent different pharmacological approaches with substantially different clinical outcomes. Tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for weight management, is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist — the first approved therapy in this dual-agonist class. Dulaglutide, marketed as Trulicity, is a once-weekly GLP-1 receptor agonist that has been widely prescribed for type 2 diabetes since its approval in 2014.

The tirzepatide vs dulaglutide comparison is uniquely informative because these agents were evaluated head-to-head in the SURPASS clinical trial programme, providing direct comparative evidence that is often lacking between therapies in this space. The SURPASS-2 trial demonstrated clear superiority of tirzepatide over semaglutide for glycaemic control, placing tirzepatide above even the most potent single GLP-1 agonists. Comparisons with dulaglutide (marketed as Trulicity), which represents a less potent but well-established GLP-1 agonist, reveal even larger efficacy differentials.

The Mounjaro vs Trulicity discussion is clinically relevant for prescribing decisions in type 2 diabetes, particularly given the availability of cardiovascular outcome data from the SURPASS-CVOT trial comparing these two agents directly. This head-to-head evidence base makes the tirzepatide vs dulaglutide comparison one of the most data-rich within the incretin-based therapy landscape.

Mechanism of Action

Dulaglutide activates the GLP-1 receptor selectively, producing the canonical effects of GLP-1 receptor agonism: glucose-dependent insulin secretion from pancreatic beta cells, suppression of inappropriate glucagon secretion, delayed gastric emptying, and central appetite suppression. It consists of a modified GLP-1 analogue fused to a modified immunoglobulin G4 (IgG4) Fc fragment, which extends its circulating half-life through reduced renal clearance and FcRn-mediated recycling.

Tirzepatide engages two incretin receptors simultaneously. It activates both the GIP receptor and the GLP-1 receptor through a single-molecule dual agonist design based on a modified GIP peptide sequence with GLP-1 receptor cross-reactivity. Research suggests that GIP receptor agonism may enhance insulin sensitivity in adipose tissue, promote lipid storage in appropriate depots, and potentially complement the appetite-suppressive and insulinotropic effects of GLP-1 receptor activation. The combination of these two receptor pathways appears to produce additive or synergistic effects on glycaemic control and weight reduction.

The mechanistic distinction between single (dulaglutide) and dual (tirzepatide) incretin receptor agonism has been explored in the SURPASS-2 trial, where Frías et al. (2021) compared tirzepatide directly against semaglutide (the most potent approved GLP-1 agonist at the time), demonstrating that dual agonism produced superior outcomes even compared to the best-in-class single GLP-1 agonist.

Clinical Evidence

The SURPASS programme provides extensive evidence for the tirzepatide vs dulaglutide comparison. While no single SURPASS trial used dulaglutide as a direct comparator arm, the SURPASS-CVOT trial (Nicholls et al., 2025) was a landmark cardiovascular outcomes trial that randomised patients directly to tirzepatide versus dulaglutide, providing definitive head-to-head evidence for cardiovascular safety and efficacy.

In the SURPASS-CVOT trial, tirzepatide demonstrated non-inferiority to dulaglutide for major adverse cardiovascular events (MACE) in patients with type 2 diabetes and established atherosclerotic cardiovascular disease. Post hoc analyses by Nissen et al. (2026) examined cardiorenal outcomes from this trial, providing additional comparative data on renal function preservation and cardiovascular biomarkers. The SURPASS-SWITCH study (Violante-Ortiz et al., 2026) further examined outcomes in patients transitioning from dulaglutide to tirzepatide.

Dulaglutide’s independent evidence base includes the AWARD trial programme (multiple studies in type 2 diabetes) and the REWIND cardiovascular outcomes trial (Gerstein et al., 2019), which demonstrated a reduction in major adverse cardiovascular events with dulaglutide versus placebo — notably, one of the few GLP-1 agonist trials to include a majority of participants without established cardiovascular disease.

Efficacy Comparison

The efficacy differential between tirzepatide and dulaglutide is substantial across both glycaemic and weight endpoints. In the SURPASS programme, tirzepatide at its highest dose (15 mg) produced HbA1c reductions of approximately 2.3-2.6 percentage points and body weight reductions of approximately 11-13% in type 2 diabetes populations. By comparison, dulaglutide 1.5 mg in the AWARD programme produced HbA1c reductions of approximately 1.1-1.5 percentage points and weight reductions of approximately 2-3 kg.

The SURMOUNT programme, evaluating tirzepatide specifically for obesity (Jastreboff et al., 2022), demonstrated mean weight reductions of approximately 22.5% with tirzepatide 15 mg over 72 weeks in the SURMOUNT-1 trial. Dulaglutide is not approved for weight management and has not been evaluated in dedicated obesity trials, reflecting the substantially different weight loss magnitudes these two agents produce. The Mounjaro vs Trulicity comparison for weight outcomes thus reveals a marked advantage for tirzepatide.

The SURPASS-SWITCH data (Violante-Ortiz et al., 2026) demonstrated additional glycaemic and weight improvements in patients switching from dulaglutide to tirzepatide, confirming that the efficacy differential translates to clinical benefit even in patients already receiving GLP-1 receptor agonist therapy.

Safety and Tolerability

Both tirzepatide and dulaglutide share gastrointestinal adverse events as their most common side effects, consistent with incretin receptor agonism. Nausea, diarrhoea, and vomiting occur with both agents and are typically dose-dependent and self-limiting. The overall incidence of gastrointestinal events tends to be somewhat higher with tirzepatide, likely reflecting its greater pharmacological potency and the additive effects of dual receptor stimulation.

The SURPASS-CVOT safety data provide the most comprehensive comparative assessment. Discontinuation rates due to adverse events and serious adverse event rates were broadly similar between tirzepatide and dulaglutide in this large-scale trial. Nicholls et al. (2025) reported that the overall safety profiles were consistent with prior experience for both agents.

Dulaglutide’s safety profile benefits from more extensive post-marketing surveillance, given its longer time on the market. The REWIND trial (Gerstein et al., 2019) provided long-term safety data over a median follow-up of 5.4 years, demonstrating acceptable tolerability. Tirzepatide’s post-marketing experience is accumulating but remains more limited. Both agents carry class-related warnings for thyroid C-cell tumours, pancreatitis, and diabetic retinopathy complications.

Pharmacokinetics

Both tirzepatide and dulaglutide are administered as once-weekly subcutaneous injections, offering comparable dosing convenience. However, their molecular designs and pharmacokinetic properties differ in key respects.

Dulaglutide achieves its extended half-life (approximately 5 days) through fusion of a GLP-1 analogue to a modified IgG4 Fc fragment. This large molecular weight (~63 kDa) reduces renal clearance and enables FcRn-mediated endosomal recycling. It is administered as a single-use pre-filled pen with an automatic needle insertion mechanism that conceals the needle, designed to improve patient acceptance.

Tirzepatide has a half-life of approximately 5 days, achieved through acylation with a C20 fatty di-acid moiety that promotes albumin binding — a mechanism similar to semaglutide. Its molecular weight is substantially lower than dulaglutide’s (~5 kDa vs ~63 kDa), which may influence tissue distribution and receptor engagement kinetics. Tirzepatide is available in a pre-filled single-dose pen across multiple dose levels (2.5, 5, 7.5, 10, 12.5, and 15 mg), allowing for gradual dose escalation to improve tolerability.

Both agents are metabolised through proteolytic degradation and are not significantly eliminated by renal or hepatic clearance, making dose adjustments unnecessary in mild-to-moderate organ impairment for either compound.

Current Research Status

Tirzepatide holds FDA approval for type 2 diabetes (Mounjaro, 2022) and chronic weight management (Zepbound, 2023). The SURPASS-CVOT results have established its cardiovascular safety compared to dulaglutide. Ongoing research is exploring tirzepatide in obstructive sleep apnoea, heart failure with preserved ejection fraction, NASH/MASH, and chronic kidney disease. The SURMOUNT-2 trial (Garvey et al., 2023) and SURMOUNT-3 trial (Wadden et al., 2023) have expanded the obesity evidence base.

Dulaglutide (Trulicity) is FDA-approved for type 2 diabetes with a cardiovascular risk reduction indication based on REWIND data. It remains widely prescribed globally, though its market position has been challenged by the introduction of more efficacious agents including tirzepatide and semaglutide. Research interest in dulaglutide has shifted primarily to real-world effectiveness studies and cost-effectiveness analyses.

The broader competitive landscape continues to evolve, with triple-receptor agonists such as retatrutide in development. Network meta-analyses continue to position tirzepatide and dulaglutide within the growing armamentarium of incretin-based therapies, helping to inform treatment sequencing and selection decisions in clinical practice.

Summary

Tirzepatide and dulaglutide are both once-weekly injectable incretin-based therapies for type 2 diabetes, but they differ fundamentally in receptor pharmacology and clinical outcomes. Tirzepatide is a dual GIP/GLP-1 receptor agonist that produces substantially greater HbA1c reductions (up to 2.6 percentage points) and weight loss (up to 22.5% in obesity trials) compared to dulaglutide, a selective GLP-1 receptor agonist with more modest effects (HbA1c reductions of approximately 1.1-1.5 percentage points). Both agents have demonstrated cardiovascular safety, with the SURPASS-CVOT trial directly comparing tirzepatide to dulaglutide and the REWIND trial demonstrating dulaglutide’s cardiovascular benefit versus placebo. Tirzepatide is approved for both diabetes and obesity, while dulaglutide is approved only for diabetes. The Mounjaro vs Trulicity comparison favours tirzepatide for efficacy across endpoints, though dulaglutide benefits from longer post-marketing experience and established real-world outcomes data.

References

• Frías JP et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. PMID: 34170647
• Nicholls SJ et al. (2025). Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. New England Journal of Medicine. PMID: 41406444
• Gerstein HC et al. (2019). Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. PMID: 31189511
• Garvey WT et al. (2023). Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. PMID: 37385275
• Violante-Ortiz R et al. (2026). Safety and efficacy of switching from dulaglutide to tirzepatide across clinically relevant baseline characteristics in participants with T2D: subgroup analysis of SURPASS-SWITCH. BMJ Open Diabetes Research and Care. PMID: 41912265
• Nissen SE et al. (2026). Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial. JAMA Cardiology. PMID: 41903177
• Wadden TA et al. (2023). Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nature Medicine. PMID: 37840095